This page collects WhisperX intelligence signals tagged #CAR-T Therapy. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
Immix Biopharma shares are rising following a significant vote of confidence from Wall Street. Morgan Stanley has initiated coverage of the clinical-stage biotech company with an Overweight rating, signaling a bullish outlook on its lead CAR-T cell therapy candidate. This move by a major financial institution immediate...
Caribou Biosciences' stock price surged following a critical regulatory milestone. The U.S. Food and Drug Administration (FDA) granted its CB-010 therapy a Regenerative Medicine Advanced Therapy (RMAT) designation. This status is reserved for regenerative medicine therapies, including cell therapies like CAR-T, that de...
Cellares Corporation has achieved a critical clinical milestone, with its automated Cell Shuttle platform being used to manufacture the CAR-T cell therapy for the first patient infusions in Cabaletta Bio's clinical trial. This marks a significant validation point for Cellares' integrated, automated manufacturing techno...
A small but striking clinical trial has delivered results that could redefine the treatment of multiple myeloma. At the American Association for Cancer Research meeting, researchers reported that all 20 patients with high-risk smoldering multiple myeloma—a precursor to active cancer—had no detectable myeloma cells in t...
Kyverna Therapeutics is preparing to challenge the established boundaries of cell therapy, announcing plans to seek FDA approval for a personalized CAR-T treatment targeting stiff person syndrome—a rare and debilitating neurological autoimmune disorder. The company's one-time therapy demonstrated significant improvemen...